Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants - pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

In this pooled analysis of mCRC patients, mutations in KRAS, and BRAF were associated with inferior PFS and OS compared to patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared to unmutated tumors with KRAS G12C and G13D being associated with rather poor survival.

from Cancer via ola Kala on Inoreader http://ift.tt/294VdqW
via IFTTT